Biomm SA
BOVESPA:BIOM3

Watchlist Manager
Biomm SA Logo
Biomm SA
BOVESPA:BIOM3
Watchlist
Price: 8.97 BRL 0.22%
Market Cap: 1.1B BRL
Have any thoughts about
Biomm SA?
Write Note

Relative Value

The Relative Value of one BIOM3 stock under the Base Case scenario is 5.31 BRL. Compared to the current market price of 8.97 BRL, Biomm SA is Overvalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIOM3 Relative Value
Base Case
5.31 BRL
Overvaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
52
vs Industry
40
Median 3Y
5.4
Median 5Y
9.7
Industry
8
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-11.8
Industry
23.7
vs History
vs Industry
Median 3Y
-9
Median 5Y
-9.2
Industry
22.8
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-7.5
Industry
26.6
vs History
84
vs Industry
18
Median 3Y
4
Median 5Y
5.2
Industry
2.6
vs History
60
vs Industry
36
Median 3Y
6.1
Median 5Y
9.6
Industry
7.8
vs History
60
vs Industry
13
Median 3Y
33.1
Median 5Y
40.7
Industry
9.2
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-16.2
Industry
4.7
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-13.7
Industry
4.2
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.3
Industry
6.2
vs History
vs Industry
Median 3Y
-8.5
Median 5Y
-9.4
Industry
3.9
vs History
41
vs Industry
31
Median 3Y
2.3
Median 5Y
3.2
Industry
4.8

Multiples Across Competitors

BIOM3 Competitors Multiples
Biomm SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BR
Biomm SA
BOVESPA:BIOM3
1.1B BRL 9.2 -14.5 -16 -13.5
US
Abbvie Inc
NYSE:ABBV
334.6B USD 6.1 63.1 15.5 23.7
US
Amgen Inc
NASDAQ:AMGN
172.7B USD 5.6 55.1 19.5 35.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
125.3B USD 12.1 -254.8 27.2 28.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
111.4B USD 8.2 25.7 22.4 24.8
US
Gilead Sciences Inc
NASDAQ:GILD
108.2B USD 3.9 102.7 9.7 12.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 923 -490.7 -534.4 -520.1
AU
CSL Ltd
ASX:CSL
145.3B AUD 6.6 36.8 22.5 28
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.8 -61.1 -55.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38.1B USD 16.2 -521.3 230.7 355.1
KY
Beigene Ltd
SSE:688235
248.5B CNY 11.2 -56.8 -35.3 -35.3
P/E Multiple
Earnings Growth
BR
Biomm SA
BOVESPA:BIOM3
Average P/E: 56.7
Negative Multiple: -14.5
N/A
US
Abbvie Inc
NYSE:ABBV
63.1
406%
US
Amgen Inc
NASDAQ:AMGN
55.1
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -254.8
38%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.7
56%
US
Gilead Sciences Inc
NASDAQ:GILD
102.7
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A
AU
CSL Ltd
ASX:CSL
36.8
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.8 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -521.3 N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -56.8 N/A
EV/EBITDA Multiple
EBITDA Growth
BR
Biomm SA
BOVESPA:BIOM3
Average EV/EBITDA: 49.6
Negative Multiple: -16
N/A
US
Abbvie Inc
NYSE:ABBV
15.5
28%
US
Amgen Inc
NASDAQ:AMGN
19.5
64%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.4
53%
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
9%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A
AU
CSL Ltd
ASX:CSL
22.5
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
230.7
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35.3 N/A
EV/EBIT Multiple
EBIT Growth
BR
Biomm SA
BOVESPA:BIOM3
Average EV/EBIT: 72.6
Negative Multiple: -13.5
N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
35.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.6
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.8
54%
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.1 N/A
AU
CSL Ltd
ASX:CSL
28
55%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
355.1
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35.3 N/A

See Also

Discover More
Back to Top